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Wolfram syndrome, or DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy (OA), and 1 
deafness), is a neurodegenerative disorder with heterogeneous clinical manifestations caused by 2 
homozygous or compound heterozygous recessive mutations in the WFS1 gene (OMIM 606201).1 3 
More recently, the phenotypic spectrum has expanded to include patients with dominant 4 
inheritance and limited clinical features, in particular OA in association with diabetes mellitus and/or 5 
sensorineural deafness.1 WFS1 encodes for an endoplasmic reticulum transmembrane protein, 6 
Wolframin, which is highly expressed in retinal tissues, including retinal ganglion cells, the 7 
photoreceptor inner segments, and the inner nuclear layer (INL) of the human eye, and mouse 8 
Müller cells.2,3 Thinning of the peripapillary nerve fibre and macular retinal ganglion cell layers are 9 
typical features of WFS1-related optic atrophy, but careful genotype-phenotype correlations have 10 
not yet been established. Here, we report on a comprehensive macular OCT imaging study of 14 11 
patients with OA secondary to mutations in WFS1 and the identification of a distinct outer plexiform 12 
layer (OPL) abnormality, which associates exclusively with dominant missense WFS1 mutations 13 
(Table 1, available at www.aaojournal.org). 14 
 Averaged B-scans of 26 eyes from 14 patients with confirmed pathogenic WFS1 mutations 15 
were retrospectively reviewed from our SpectralisTM (Heidelberg Engineering Ltd., Heidelberg, 16 
Germany) databases. A prominent feature in the macular SD-OCT images of 15 eyes from 8 patients 17 
harbouring dominant WFS1 mutations (Patients 1-8) was an abnormal reflectivity of the OPL, which 18 
was not observed in 11 eyes from 6 patients with recessive WFS1 mutations (Figure 1 and Table 1, 19 
available at www.aaojournal.org). The OPL was comprised of three distinct laminae: an innermost 20 
highly reflective lamina; a middle non-reflective lamina; and an outermost highly reflective lamina. 21 
To a certain extent, OPL thickness varied depending on the angle between the OCT laser beam and 22 
the retinal layers. Beam positions that were more perpendicular to the Henle’s fibre tracks resulted 23 
in a thicker OPL compared with beam positions that were parallel to these tracks, as illustrated by 24 
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the left eye of Patient 5 (Figure 1). However, in several eyes, an abnormally thick OPL was visualized 25 
even with straight OCT beam positions, as for Patient 6 (Figure 1). In the majority of patients, the 26 
middle OPL lamina formed a nearly confluent ring centred at the fovea and extending 1-1.5 mm 27 
from the foveolar centre up to the optic disc. Perifoveal volumetric retinal scans were obtained for 28 
22 eyes from 12 patients in our WFS1 cohort. Automated segmentation and retinal layer thickness 29 
analysis were carried out using the automated retinal Heidelberg Engineering segmentation tool 30 
included in the Spectralis Glaucoma Module software (version 6.0) after manual confirmation of 31 
each layer (Table 2, available at www.aaojournal.org).  Marked thinning of the GCL-IPL complex was 32 
observed consistent with OA. All 11 eyes with abnormal OPL lamination had significantly thicker OPL 33 
and, more importantly, combined OPL and ONL complex compared with control eyes, or the eyes of 34 
patients without OPL lamination. Compared with control eyes, INL thickness was increased in 4 eyes 35 
(Patients 2, 5, 8) with INL cystoid changes (Figure 1), but also in 5 other eyes with OPL lamination 36 
and in 3 eyes without OPL abnormality (Table 2, available at www.aaojournal.org). Our study had 37 
ethical and institutional approval and its design complied with the Declaration of Helsinki. 38 
We have identified a previously unreported macular OCT feature in patients with Wolfram-39 
related optic atrophy that is associated with dominant, but not recessive, WFS1 mutations. The 40 
lamination of the OPL was characterised by three distinct sublayers: (1) an innermost highly-41 
reflective lamina, similar to what is frequently identified as the OPL in normal eyes; (2) a non-42 
reflective cleft-like middle lamina; and (3) an outermost highly-reflective lamina with characteristics 43 
of Henle’s fibre layer. Our retrospective study did not enable a systematic evaluation of the effect of 44 
angle changes on the OPL reflectivity. Further work is needed to clarify whether the outermost 45 
lamina has truly abnormal reflectivity and whether the middle lamina represents an additional 46 
spatial structure or merely abnormal OCT reflectivity. However, as the thickness of combined OPL 47 
and ONL complex should not be sensitive to OCT angle changes, its significantly increased thickness 48 
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in eyes with abnormal OPL lamination suggests that an additional space could indeed account for the 49 
laminated OPL structure observed in this patient subgroup with dominant WFS1 mutations. 50 
Taking into consideration the spatial relationships between the three OPL laminae and 51 
previously published histological studies,4 we propose that the middle cleft-like lamina is located 52 
between the synaptic and pedicles sublayers of the OPL. This region has also been shown to possess 53 
a particular retinal architecture with bending Müller cells.5 Wolframin is highly expressed in Müller 54 
cells and this cell type has been implicated in the development of OPL and INL edema, and changes 55 
within Henle’s fibre layer.4,5 The Müller cell is, therefore, an attractive candidate for the 56 
development of the observed OPL lamination. 57 
 Interestingly, OPL lamination was only associated with dominant missense WFS1 mutations. 58 
It was not identified in any of the 6 patients harbouring recessive homozygous or compound 59 
heterozygous WFS1 mutations. This distinct OPL abnormality has not previously been reported in the 60 
context of optic atrophy and it could represent a specific deleterious effect of dominant WFS1 61 
mutations. The missense variants identified in our patients are predicted to result in only a minor 62 
reduction in wolframin protein level.1 Depletion of the native wild-type wolframin protein, which is 63 
thought to be the major pathophysiological mechanism in recessive Wolfram syndrome, is therefore 64 
unlikely to be implicated in the aetiology of the OPL lamination. Instead, dominant missense WFS1 65 
mutations could result in a dysfunctional aberrant wolframin protein. 66 
WFS1 is a highly polymorphic gene and determining the mode of inheritance or the 67 
pathological significance of a specific WFS1 variant is not always straightforward, especially in 68 
singleton cases with no access to other family members. Our study has revealed an interesting 69 
association between dominant missense WFS1 mutations and distinct OPL lamination on SD-OCT, 70 
which was not observed in patients with recessive WFS1 mutations. Future work in other 71 
independent patient cohorts with Wolfram syndrome will confirm whether this OCT feature could be 72 
used to distinguish between dominant and recessive forms of the disease. 73 
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A figure legend:  90 
Figure 1.  Macular SD-OCT images of Patient 1 showing outer plexiform layer (OPL) lamination and of 91 
Patient 13 without this defect (upper panel). The lower panels show OCT images of Patients 2-8 with 92 
OPL lamination, with the right eye on the left and the left eye on the right. The localization of the 93 
layers that were not imaged through the optical axis are indicated within the inserts. The yellow 94 
arrows indicate the cleft-like middle structure of the OPL. The red arrows highlight areas of cystoid 95 
inner nuclear layer (INL) edema.96 
 
  
 
 
 

Table 1. WFS1 genotype and clinical characteristics of the patients in our study cohort. 
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WFS1 mutation(s)* Extraocular findings 
OA 
age 
(y)** 
BCVA 
(logMAR) 
Macular 
SD-OCT 
RE LE Age (y)** 
OPL 
cleft*** 
1 F AD (1) c.2390A>T: p.Asp797Val SNHL, DM2 45 1.10 NI 69 + 
2 F AD (2) c.2051C>T: p.Ala684Val 
SNHL, 
epilepsy, 
hypertension 
5 0.60 0.60 46 + 
3 M AD (2) c.2051C>T: p.Ala684Val SNHL 23 0.48 0.60 23 + 
4 F AD (3) c.968A>G: p.His323Arg SNHL U 0.30 0.43 44 + 
5 F AD (3) c.968A>G: p.His323Arg SNHL 4 0.00 0.00 8 + 
6 M 
de 
novo 
(4) 
c.937C>T: p.His313Tyr 
c.-170-9_14dupTGCCCC 
SNHL, DM1, 
short stature 7 0.10 0.20 10 + 
7 F AD (5) c.2051C>T: p.Ala684Val SNHL 78 1.98 1.98 78 + 
8 F AD (6) c.2161A>T: p.Asn721Tyr SNHL 50 1.98 1.98 51 + 
9 M AR (7) 
c.505G>A: p.Glu169Lys 
c.874C>A: p.Pro292Thr 
DM1, DI, 
NB 9 2.28 2.28 45 - 
10 M AR (7) 
c.505G>A: p.Glu169Lys 
c.874C>A: p.Pro292Thr 
DM1, DI, 
NB U 1.30 NI 46 - 
11 F AR (8) 
c.2648_2651delTCTT: 
p.Phe883SerfsX68 
c.1597C>T: p.Pro533Ser 
DI 
UC 23 0.60 0.60 44 - 
12 F AR (8) 
c.2648_2651delTCTT: 
p.Phe883SerfsX68 
c.1597C>T: p.Pro533Ser 
DI 
UC 37 0.78 0.78 52 - 
13 F AR (9) 
c.2643_2644delC: p.Phe883LeufsX56  
(homozygous) 
SNHL, DM1, 
DI 
PS, NEU 
15 1.30 1.30 25 - 
14 F AR (10) 
c.409_424dup1: p.Val142GlyfsX10 
c.2262_2263delCT: p.Cys755SerfsX3 SNHL, DM1 31 1.00 1.00 35 - 
 
* WFS1 genetic testing was conducted by the West Midlands Regional Genetic Laboratory, Birmingham, UK.  
** Age at the time of diagnosis of optic atrophy (OA) and when macula SD-OCT imaging was performed.  Images were 
retrieved from the SpectralisTM (Heidelberg Engineering Ltd., Heidelberg, Germany) databases of Moorfields Eye 
Hospital, London, UK and the Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK. Our study had 
local ethical and institutional approval, and its design complied with the Declaration of Helsinki. 
***The presence (+) or absence (-) of an outer plexiform layer (OPL) lamination is indicated. 
Abbreviations: DI, Diabetes insipidus; DM1, Diabetes mellitus type 1; DM2, Diabetes mellitus type 2; LE, left eye; NB, 
Neurogenic bladder; NEU, intermittent myoclonus, occasional balance problem, postural hypotension; NI, not 
included into the study; NP, not performed; OA; optic atrophy; OPL; outer plexiform layer; PS, bipolar affective 
disorder RE, right eye; RNFL, peripapillary retinal nerve fiber layer thickness; SNHL, sensorineural hearing loss; U, 
Unknown; UC, urinary and faecal incontinence. 
